Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

By P. Goodwin, M. Ennis, K. Pritchard, M. Trudeau, J. Koo, Y. Madarnas, W. Hartwick, B. Hoffman, N. Hood. Journal of Clinical Oncology, 2002

670 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/498d557ee9aec24680f989bec3d3c9c56ddb7b33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Michael Pollak

In Molecular Biology

1. Michael Pollak
2. Funda Meric-Bernstam
3. Nahum Sonenberg
4. J. Slingerland
5. David M. Sabatini
6. M. Karin
7. A. Budanov

In Oncology

1. M. Hung
2. J. Slingerland
3. G. Hortobagyi
4. Michael Pollak

Citations in the corpus

• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. (2006, background): “The indirect mechanism may be of considerable importance in subjects with high insulin levels and/or cancers with high levels of insulin and/or hybrid insulin/IGF-I receptors (17, 18), where there is emerging evidence that ligand levels influence risk and prognosis (19, 20).”
• Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis (2010, background): “Another study excluded diabetes [19] and reported adjusted HR = 1.”
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009, background): “In clinical studies, elevated insulin levels have been associated with poorer outcomes in patients with breast cancer.(28-30) Metformin has been shown to reduce insulin levels by 22% in nondiabetic hyperinsulinemic women with early-stage breast cancer.”
• Comprehensive geriatric assessment for older patients with cancer. (2007, background): “Hyperinsulinemia is associated with a worse diseasespecific survival in prostate cancer,(20) colon cancer,(19) and breast cancer.(21) Obesity is associated with a worse progression-free survival (PFS) and OS in patients with ovarian cancer.”
• Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention (2017, background): “Elevated fasting insulin is associated with poor breast cancer outcome.(110) Hyperinsulinemia reduces sex hormone-binding globulin levels and increases estrogen bioavailability, thereby increasing breast cancer risk.”
• Physical activity and survival after breast cancer diagnosis. (2004, background): “Physical activity might also improve survival through acute and chronic improvements in insulin resistance and reduction in hyperinsulinemia.(40) The associations we observed may change over time as the use of aromatase inhibitors to suppress hormone levels becomes more popular.”